Progesterone Receptor Agonists and Antagonists as Anticancer Agents

被引：3
|
作者：
Chakraborty, A. [1 ]
Chatterjee, S. [1 ]
Roy, P. [1 ]
机构：
[1] Indian Inst Technol Roorkee, Dept Biotechnol, Mol Endocrinol Lab, Roorkee 247667, Uttar Pradesh, India
来源：
MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2010年 / 10卷 / 06期
关键词：
Progesterone receptor; progestagens; agonists; antagonists; anti-cancer; HORMONE REPLACEMENT THERAPY; BREAST-CANCER CELLS; TRANSCRIPTIONAL ACTIVITY; PENICILLIUM-OBLATUM; INHIBITORY FUNCTION; ENDOMETRIAL CANCER; SIGNALING PATHWAYS; ESTROGEN-RECEPTOR; GENE-EXPRESSION; DOWN-REGULATION;
D O I：
10.2174/138955710791384108
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Progesterone is a major female steroid hormone produced by the ovarian corpus luteum and by the placental syncyiotrophoblast during the second trimester. The biological effects of this steroid hormone are mediated by the ubiquitously expressed progesterone receptor. The exact link between progesterone and female reproductive organ cancer is a controversial issue with various cross-talks. The present review summarizes recent trends in the development of some (anti) progestagen in the cure and management of breast and uterine cancers.
引用
收藏
页码：506 / 517
页数：12
相关论文
共 50 条
  • [21] Latest advances in cannabinoid receptor antagonists and inverse agonists
    Muccioli, Giulio G.
    Lambert, Didier M.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2006, 16 (10) : 1405 - 1423
  • [22] Structure and the Anticancer Activity of Vitamin D Receptor Agonists
    Powala, Agnieszka
    Zolek, Teresa
    Brown, Geoffrey
    Kutner, Andrzej
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (12)
  • [23] Neurokinin-1 Receptor Antagonists as Anticancer Drugs
    Munoz, Miguel
    Covenas, Rafael
    LETTERS IN DRUG DESIGN & DISCOVERY, 2019, 16 (10) : 1110 - 1129
  • [24] Hybrid anticancer agents: Isothiocyanate-progesterone conjugates as chemotherapeutic agents and insights into their cytotoxicities
    Adsule, Shreelekha
    Banerjee, Sanjeev
    Ahmed, Fakhara
    Padhye, Subhash
    Sarkar, Fazlul H.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (03) : 1247 - 1251
  • [25] Neuropeptide Y (NPY) family of hormones: Progress in the development of receptor selective agonists and antagonists
    Balasubramaniam, A
    CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (15) : 1165 - 1175
  • [26] Recent patent trends in the field of progesterone receptor agonists and modulators
    Schmees, Norbert
    Weinmann, Hilmar
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (11) : 1521 - 1534
  • [27] Improving the developability profile of pyrrolidine progesterone receptor partial agonists
    Kallander, Lara S.
    Washburn, David G.
    Hoang, Tram H.
    Frazee, James S.
    Stoy, Patrick
    Johnson, Latisha
    Lu, Qing
    Hammond, Marlys
    Barton, Linda S.
    Patterson, Jaclyn R.
    Azzarano, Leonard M.
    Nagilla, Rakesh
    Madauss, Kevin P.
    Williams, Shawn P.
    Stewart, Eugene L.
    Duraiswami, Chaya
    Grygielko, Eugene T.
    Xu, Xiaoping
    Laping, Nicholas J.
    Bray, Jeffrey D.
    Thompson, Scott K.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (01) : 371 - 374
  • [28] Discovery of non-peptide bradykinin B2 receptor antagonists and agonists
    Abe, Y
    Sawada, Y
    Imai, K
    Kayakiri, H
    JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN, 2005, 63 (09) : 852 - 863
  • [29] A multiplexed screening method for agonists and antagonists of the estrogen receptor protein
    Li, Zhonghui
    Yan, Ming
    Li, Zhoumin
    Vuki, Maika
    Wu, Dan
    Liu, Fei
    Zhong, Wenying
    Zhang, Luyong
    Xu, Danke
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2012, 403 (05) : 1373 - 1384
  • [30] Urokinase receptor and resistance to targeted anticancer agents
    Gonias, Steven L.
    Hu, Jingjing
    FRONTIERS IN PHARMACOLOGY, 2015, 6
12345